Deregulation of cyclin E meets dysfunction in p53: Closing the escape hatch on breast cancer

被引:17
作者
Barton, Michelle Craig
Akli, Said
Keyomarsi, Khandan
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA
[3] Univ Texas, Hlth Sci Ctr, Grad Program Genes & Dev, Grad Sch Biomed Sci, Houston, TX USA
[4] Univ Texas, Hlth Sci Ctr, Canc Biol Program, Grad Sch Biomed Sci, Houston, TX USA
关键词
D O I
10.1002/jcp.20818
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
In this review, we focus on pathways intersecting through p53 and cyclin E, highlighting how oncogenic effects of cyclin E deregulation, especially overexpression of shortened or low molecular weight (LMW) forms of cycl in E protein, are amplified by loss of regulatory control through p53 to promote tumor development. Expression of cyclin E protein promotes progression into S-phase, an activity opposed by p53-regulated activation of checkpoint controls or apoptosis. Loss of p53 function is an escape hatch by which tumor cells, initiated by a number of means including cyclin E deregulation, can avoid cell cycle arrest or cell death and progress through further stages of unchecked deregylation and growth. To determine how this escape hatch is opened and, ultimately, how to close it, we must understand the networks of normal signaling and processing in a cell and where they intersect.
引用
收藏
页码:686 / 694
页数:9
相关论文
共 126 条
[91]  
PATEL B, 2003, P AN M AM SOC CLIN, V22, P233
[92]  
PIERGA JY, 2003, P AN M AM SOC CLIN, V22, P210
[93]   Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms [J].
Porter, DC ;
Zhang, N ;
Danes, C ;
McGahren, MJ ;
Harwell, RM ;
Faruki, S ;
Keyomarsi, K .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (18) :6254-6269
[94]   Unleashing the power of p53: lessons from mice and men [J].
Poyurovsky, MV ;
Prives, C .
GENES & DEVELOPMENT, 2006, 20 (02) :125-131
[95]   MDMX inhibits the p300/CBP-mediated acetylation of p53 [J].
Sabbatini, P ;
McCormick, F .
DNA AND CELL BIOLOGY, 2002, 21 (07) :519-525
[96]   Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors [J].
Schwartz, GK ;
O'Reilly, E ;
Ilson, D ;
Saltz, L ;
Sharma, S ;
Tong, W ;
Maslak, P ;
Stoltz, M ;
Eden, L ;
Perkins, P ;
Endres, S ;
Barazzoul, J ;
Spriggs, D ;
Kelsen, D .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) :2157-2170
[97]   Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma [J].
Schwartz, GK ;
Ilson, D ;
Saltz, L ;
O'Reilly, E ;
Tong, W ;
Maslak, P ;
Werner, J ;
Perkins, P ;
Stoltz, M ;
Kelsen, D .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (07) :1985-1992
[98]   Cyclin E overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage [J].
Scuderi, R ;
Palucka, KA ;
Pokrovskaja, K ;
Bjorkholm, M ;
Wiman, KG ;
Pisa, P .
BLOOD, 1996, 87 (08) :3360-3367
[99]  
Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393
[100]  
Shapiro GI, 2001, CLIN CANCER RES, V7, P1590